Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Activated Protein C Induces Stabilization of the Outer Retinal Barrier and Inhibits Laser Induced Choroidal Neovascularization in a Murine Model

Tami Livnat, PhD, Yael Nisgav, Msc, Ivan Budnik, MDPhD, Yehonatan Weinberger, MD, Rima Dardik, PhD, Gili Kenet, MD, Dov Weinberger, MD

Blood (2018) 132 (Supplement 1): 73.

https://doi.org/10.1182/blood-2018-99-111375

Published: 2018

Journal Articles

Whole Blood Transcriptional Profiling Reveals Highly Deregulated Atherosclerosis Genes in Myeloproliferative Cancer

Vibe Skov, PhD, Mads Thomassen, PhD, Lasse Kjær, PhD, Caroline Riley, PhD, Thomas Stauffer Larsen, MD PhD, Ole Weis Bjerrum, MD PhD, Torben A Kruse, Hans Carl Hasselbalch, Professor, dr.MD

Blood (2018) 132 (Supplement 1): 3071.

https://doi.org/10.1182/blood-2018-99-117981

Published: 2018

Journal Articles

DNA Aptamer Against Anti- Programmed Cell Death-1 (Anti-PD1-Apt) Induces Robust Anti-Leukemic Activity In Vitro and In Vivo Humanized NSG Mice with Myeloid Leukemia Xenografts

Santhana Gowri Thangavelu Devaraj, PhD, Lokesh Ganesh Lakshmana Rao, PhD, Youli Zu, MD PhD, Jenny Chang, MD, Swami P. Iyer, MD

Blood (2017) 130 (Supplement 1): 1373.

https://doi.org/10.1182/blood.V130.Suppl_1.1373.1373

Published: 2017

Journal Articles

Are Chronic Myeloproliferative Neoplasms Associated with Age-Related Macular Degeneration?

Marie Bak, MD PhDstudent, Torben Lykke Sørensen, Esben Meulengracht Flachs, Ann-Dorthe Olsen Zwisler, Knud Juel, Henrik Frederiksen, Hans Hasselbalch, MD

Blood (2015) 126 (23): 4444.

https://doi.org/10.1182/blood.V126.23.4444.4444

Published: 2015

Journal Articles

“Red Cell Complement Loading In PNH Patients On Eculizumab Is Associated With a C3 Polymorphism Which Influences C3 Function, Predicts For Increased Extravascular Hemolysis and Provides a Rationale For C3 Inhibition.”

Praveen Kaudlay, MBBS, MRCP, Haiying Hua, MD, Guansheng He, MD, Darren J Newton, PhD, Abraham M Varghese, MB ChB, Talha Munir, MBBS, MRCP, FRCPath, Anita Hill, MBChB, PhD, Richard J Kelly, MBChB, Stephen John Richards, PhD, Peter Hillmen, MB ChB, PhD

Blood (2013) 122 (21): 2466.

https://doi.org/10.1182/blood.V122.21.2466.2466

Published: 2013

Journal Articles

Preclinical Development and In Vivo Evaluation Of Next-Generation Compstatin Analogs With Improved Systemic Profiles: A Novel Option For The Treatment Of Paroxysmal Nocturnal Hemoglobinuria

Daniel Ricklin, Ph.D., Antonio M. Risitano, MD, PhD, Edimara S. Reis, Ph.D., Patrizia Ricci, Yijun Huang, Ph.D., Zhuoer Lin, Ph.D., Hui Chen, Ph.D., Caterina Pascariello, Maddalena Raia, Luigi Del Vecchio, MD, Fabrizio Pane, MD, Ranillo R. G. Resuello, D.V.M., Robert A. DeAngelis, Ph.D., John D. Lambris, Ph.D.

Blood (2013) 122 (21): 1239.

https://doi.org/10.1182/blood.V122.21.1239.1239

Published: 2013

Journal Articles

Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab

Laura M Rogers, PhD, Laura S. Jacobus, MS, Anna M Button, MS, Brian K Link, MD, Thomas M Habermann, MD, Thomas E Witzig, MD, James R Cerhan, MD, PhD, George J. Weiner, MD

Blood (2013) 122 (21): 4288.

https://doi.org/10.1182/blood.V122.21.4288.4288

Published: 2013

Journal Articles

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

V. Michael Holers, Istvan Mazsaroff, PhD, Hillary Akana, Christopher G. Smith, J. Woodruff Emlen, MD, Russell C. Marians, PhD, Christopher J. Horvath, DVM

Blood (2009) 114 (22): 3021.

https://doi.org/10.1182/blood.V114.22.3021.3021

Published: 2009

Journal Articles

Factor H–related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation

Stefan Heinen, Andrea Hartmann, Nadine Lauer, Ulrike Wiehl, Hans-Martin Dahse, Sylvia Schirmer, Katharina Gropp, Tina Enghardt, Reinhard Wallich, Steffi Hälbich, Michael Mihlan, Ursula Schlötzer-Schrehardt, Peter F. Zipfel, Christine Skerka

Blood (2009) 114 (12): 2439–2447.

https://doi.org/10.1182/blood-2009-02-205641

Published: 2009

Includes: Supplemental data

NARROW

Activated Protein C Induces Stabilization of the Outer Retinal Barrier and Inhibits Laser Induced Choroidal Neovascularization in a Murine Model

Whole Blood Transcriptional Profiling Reveals Highly Deregulated Atherosclerosis Genes in Myeloproliferative Cancer

DNA Aptamer Against Anti- Programmed Cell Death-1 (Anti-PD1-Apt) Induces Robust Anti-Leukemic Activity In Vitro and In Vivo Humanized NSG Mice with Myeloid Leukemia Xenografts

Are Chronic Myeloproliferative Neoplasms Associated with Age-Related Macular Degeneration?

“Red Cell Complement Loading In PNH Patients On Eculizumab Is Associated With a C3 Polymorphism Which Influences C3 Function, Predicts For Increased Extravascular Hemolysis and Provides a Rationale For C3 Inhibition.”

Preclinical Development and In Vivo Evaluation Of Next-Generation Compstatin Analogs With Improved Systemic Profiles: A Novel Option For The Treatment Of Paroxysmal Nocturnal Hemoglobinuria

Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab

TT30, a Novel Human Protein Therapeutic, Selectively Modulates the Complement Alternative Pathway by Targeted Supplementation of Local Factor H Activity.

Factor H–related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only